AI-generated summary
The authors report a single-arm pilot study of photobiomodulation therapy in 12 head and neck cancer survivors with lymphedema. Eleven patients completed the intervention, with no adverse events reported, and the authors observed improvements in external lymphedema, symptom burden and neck range of motion from baseline to 4 weeks after treatment. The authors describe the therapy as feasible and potentially effective, and call for randomized controlled trials.
- Participants
- 12
- Who or what was studied
- Head and neck cancer survivors with lymphedema who had completed complete decongestive therapy and were 3 to 18 months past cancer treatment
- Limits stated in the abstract
- The single-arm design without a control group and the small sample of 12 patients limit conclusions about efficacy.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Trial registration. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.